These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38521549)

  • 1. Corrigendum to "External evaluation of the predictive performance of published population pharmacokinetic models of linezolid in adult patients" [Journal of Global Antimicrobial Resistance 35 (2023) 347-353].
    Qin Y; Jiao Z; Ye YR; Shen Y; Chen Z; Chen YT; Li XY; Lv QZ
    J Glob Antimicrob Resist; 2024 Mar; 36():492. PubMed ID: 38521549
    [No Abstract]   [Full Text] [Related]  

  • 2. External evaluation of the predictive performance of published population pharmacokinetic models of linezolid in adult patients.
    Qin Y; Jiao Z; Ye YR; Shen Y; Chen Z; Chen YT; Li XY; Lv QZ
    J Glob Antimicrob Resist; 2023 Dec; 35():347-353. PubMed ID: 37573945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External Evaluation of Population Pharmacokinetics and Pharmacodynamics in Linezolid-Induced Thrombocytopenia: The Transferability of Published Models to Different Hospitalized Patients.
    Ogami C; Tsuji Y; Nishi Y; Kawasuji H; To H; Yamamoto Y
    Ther Drug Monit; 2021 Apr; 43(2):271-278. PubMed ID: 33009290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External evaluation of the predictive performance of seven population pharmacokinetic models for phenobarbital in neonates.
    Ryu S; Jung WJ; Jiao Z; Chae JW; Yun HY
    Br J Clin Pharmacol; 2021 Oct; 87(10):3878-3889. PubMed ID: 33638184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation.
    Soraluce A; Barrasa H; Asín-Prieto E; Sánchez-Izquierdo JÁ; Maynar J; Isla A; Rodríguez-Gascón A
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31936614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.
    Bourgeois-Nicolaos N; Nguyen TT; Defrance G; Massias L; Alavoine L; Lefort A; Noel V; Senneville E; Doucet-Populaire F; Mentré F; Andremont A; Duval X
    Antimicrob Agents Chemother; 2014 May; 58(5):2681-7. PubMed ID: 24566182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients.
    Plock N; Buerger C; Joukhadar C; Kljucar S; Kloft C
    Drug Metab Dispos; 2007 Oct; 35(10):1816-23. PubMed ID: 17639029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External evaluation of published population pharmacokinetic models of posaconazole.
    Huang S; Ding Q; Yang N; Sun Z; Cheng Q; Liu W; Li Y; Chen X; Wu C; Pei Q
    Front Pharmacol; 2022; 13():1005348. PubMed ID: 36249756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.
    Kamp J; Bolhuis MS; Tiberi S; Akkerman OW; Centis R; de Lange WC; Kosterink JG; van der Werf TS; Migliori GB; Alffenaar JC
    Int J Antimicrob Agents; 2017 Jun; 49(6):688-694. PubMed ID: 28389352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
    Boak LM; Li J; Rayner CR; Nation RL
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus.
    Zhang HX; Sheng CC; Liu LS; Luo B; Fu Q; Zhao Q; Li J; Liu YF; Deng RH; Jiao Z; Wang CX
    Br J Clin Pharmacol; 2019 Apr; 85(4):746-761. PubMed ID: 30597603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.
    Sasaki T; Takane H; Ogawa K; Isagawa S; Hirota T; Higuchi S; Horii T; Otsubo K; Ieiri I
    Antimicrob Agents Chemother; 2011 May; 55(5):1867-73. PubMed ID: 21357301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.
    Bloomfield C; Staatz CE; Unwin S; Hennig S
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3407-14. PubMed ID: 27001806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum to "Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study" [International Journal of Antimicrobial Agents, Volume 54, Issue 5 (2019) 572-578].
    Echeverria-Esnal D; Sorli L; Prim N; Conde-Estévez D; Mateu-De Antonio J; Martin-Ontiyuelo C; Horcajada JP; Grau S
    Int J Antimicrob Agents; 2021 Dec; 58(6):106455. PubMed ID: 34756636
    [No Abstract]   [Full Text] [Related]  

  • 15. External Evaluation of Vancomycin Population Pharmacokinetic Models at Two Clinical Centers.
    Liu YX; Wen H; Niu WJ; Li JJ; Li ZL; Jiao Z
    Front Pharmacol; 2021; 12():623907. PubMed ID: 33897418
    [No Abstract]   [Full Text] [Related]  

  • 16. Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.
    Velarde-Salcedo R; Pérez-González LF; Rodríguez-Báez AS; Arriaga-García FJ; Milán-Segovia RDC; Romano-Moreno S; Medellín-Garibay SE
    Eur J Pediatr; 2023 Sep; 182(9):4143-4152. PubMed ID: 37436522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the MDR Direct Flow Chip Kit for the Detection of Multiple Antimicrobial Resistance Determinants.
    Rodríguez-Villodres Á; Galiana-Cabrera A; Torres Fink I; Duran Jiménez R; Cisneros JM; Lepe JA
    Microb Drug Resist; 2023 Aug; 29(8):381-385. PubMed ID: 36961424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum to "What and how can we learn from complex global problems for antimicrobial resistance policy? A comparative study combining historical and foresight approaches" [Journal of Global Antimicrobial Resistance 35 (2023) 110-121].
    Pitchforth E; Ali GC; Smith E; Taylor J; Rayner T; Lichten C; d'Angelo C; Gradmann C; Berridge V; Bertscher A; Allel K
    J Glob Antimicrob Resist; 2023 Dec; 35():357. PubMed ID: 38035930
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients.
    Deng C; Liu T; Wu K; Wang S; Li L; Lu H; Zhou T; Cheng D; Zhong X; Lu W
    J Clin Pharm Ther; 2013 Dec; 38(6):480-9. PubMed ID: 24033587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy.
    Huang W; Zheng Y; Huang H; Cheng Y; Liu M; Chaphekar N; Wu X
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1447-1457. PubMed ID: 35764817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.